Skip Navigation

JNCI Monographs 2004 2004(32):127-135; doi:10.1093/jncimonographs/lgh019
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Greenberg, D. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenberg, D. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

2004 © Oxford University Press

ARTICLE

Barriers to the Treatment of Depression in Cancer Patients

Donna B. Greenberg

Correspondence to: Donna B. Greenberg, MD, Department of Psychiatry, WRN 605, Massachusetts General Hospital, 55 Fruit St., Boston, MA 02114 (e-mail: dgreenberg{at}partners.org)

Major depressive disorder is a relapsing syndrome with grave morbidity and mortality. Much like asthma, it has a genetic predisposition and environmental triggers. Specific antidepressant medications alone, tested in randomized, placebo-controlled studies, show that this is a treatable condition with 65%-70% clinical response. Treatment guidelines written for psychiatric patients and patients in primary care clarify the role of medications and psychotherapy. Physicians are compelled to treat syndromes that are serious and treatable, but barriers to diagnosis and treatment of major depressive disorder in cancer patients include two major barriers to quality medical care generally: uncertainty and cost. Given uncertainty about diagnosis and treatment, cancer physicians with limited time avoid questions about emotions. Cases of depression are often missed. Mental health specialists often work in systems that are separated from oncologists by location, organization, and insurance. Most successful interventions to improve treatment of depressive disorders require multiple strategies: clinical education, enhanced role of nurses, and integrated oncology and specialist care. Recent strategies in oncology settings are reviewed. Research concepts to improve outcomes in treatment of depression include staging of depressive disorder in cancer to reveal prognosis, evaluation of depression outcomes in the context of one tumor type, new organizational models in the acute cancer setting, use of the cancer protocol, and assessment of access to care of depression in cancer survivors. Major depressive disorder in cancer is staged by positive past history, comorbid anxiety disorder or substance abuse, use of specific cancer medications that destabilize mood, and active cancer or no evidence of disease.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.